{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:24:09Z","timestamp":1793957049283,"version":"4.8.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.hlc.2024.11.018","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:31:45Z","timestamp":1744133505000},"page":"596-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Myocardial Injury Following Immune Checkpoint Inhibitors: An Australian Experience"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9220-9341","authenticated-orcid":false,"given":"Briella K.","family":"Egberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-1198","authenticated-orcid":false,"given":"Rajiv","family":"Ananthakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-3317","authenticated-orcid":false,"given":"Rebecca","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7229-2220","authenticated-orcid":false,"given":"Sivabaskari","family":"Pasupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia A.","family":"Bromley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9041-3751","authenticated-orcid":false,"given":"Woo Sze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-4265","authenticated-orcid":false,"given":"Joseph B.","family":"Selvanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2024.11.018_bib1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jamaoncol.2021.2954","article-title":"Association of adjuvant immunotherapy duration with chronic immune-related adverse events","volume":"7","author":"Rassy","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hlc.2024.11.018_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2021.09.041","article-title":"Cardiotoxicity in cancer immune-checkpoint therapy: mechanisms, clinical evidence, and management strategies","volume":"344","author":"Sun","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2024.11.018_bib3","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hlc.2024.11.018_bib4","doi-asserted-by":"crossref","first-page":"145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hlc.2024.11.018_bib5","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2024.11.018_bib6","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2024.11.018_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.hlc.2024.11.018_bib8","first-page":"385","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.hlc.2024.11.018_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2024.11.018_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.08.038","article-title":"Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: same disease, distinct challenges to face","volume":"296","author":"Veronese","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2024.11.018_bib11","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2024.11.018_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","article-title":"Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy","volume":"4","author":"Tamura","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hlc.2024.11.018_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"1","author":"Waliany","year":"2021","journal-title":"JACC. Cardio Oncol"},{"key":"10.1016\/j.hlc.2024.11.018_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jjcc.2022.07.009","article-title":"Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors","volume":"81","author":"Furukawa","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.hlc.2024.11.018_bib15","first-page":"23","article-title":"Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study","volume":"8","author":"Wang","year":"2022","journal-title":"Cardiooncology"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624019176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624019176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T22:55:50Z","timestamp":1755903350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950624019176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1443950624019176"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2024.11.018","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myocardial Injury Following Immune Checkpoint Inhibitors: An Australian Experience","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2024.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}